Julian Baines

BBI Diagnostics Group Ltd. develops and manufactures raw materials and finished test platforms for the in-vitro diagnostics market. The firm’s products include cell culture reagents, conjugates, depleted serum, disease state plasma, enzymes, finished kits, gold nanoparticles, monoclonal antibodies, normal serums, patient samples, polyclonal antibodies, recombinant antibodies, silver nanoparticles, biothreat and explosives antibodies. It’s services include custom conjugation, lateral flow assay development, 3DNA pushing assay sensitivity to the limit, test optimisation, atomo rapid platform and the novarum reader. The company was founded by John Chandler in 1986 and is headquartered in Cardiff, the United Kingdom.

Theratase Plc manufactured and supplied natural enzymes and biochemical products. It operated through its two subsidiaries Biozyme Laboratories and Seravac Biotech with development, production, marketing and distribution facilities. The company offered services to the diagnostics and medical laboratories. Theratase was founded on April 29, 1993 and is headquartered in Cardiff, WA.

International Brand Licensing Plc ownership of the Admiral and Muscle Athletic sports and fashion brands which it exploits through a licensing business model. The company through the licensing of its trademark registrations to licensees in various territories around the world, receives revenues through royalties and minimum guarantees. The company engages in the developing and exploiting portfolio of sports and lifestyle brands, trademarks, trade names and logos. It seeks to exploit the value of its brands by granting licenses to third parties authorising manufacture, marketing and sale of specified licensed products for a fixed term by reference to a particular territory. International Brand Licensing was founded in 2002 and is headquartered in London.

Quotient Diagnostics Ltd. develops diabetes testing technology. It offers pharmaceuticals, in vitro diagnostics and medical devices. The company was founded in December 2002 and is headquartered in Walton-on-Thames, the United Kingdom.

360 Genomics Ltd. provides pharmaceutical services. It develops PCR based detection system, a product that works in tandem with PointMan designed to detect non-wild type gene sequences by means of fluorescent tags. The company was founded on July 23, 2007 and is headquartered in South Glamorgan, the United Kingdom.